339 active
/
628 total (since 2015)
186
Phase 1 Active
352 total
198
Phase 2 Active
356 total
28
Phase 3 Active
43 total
3
Phase 4 Active
5 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Novartis 3 1 2
Philogen S.p.A. 3 0 1
GT Medical Technologies, Inc. 2 0 1
Cantex Pharmaceuticals 2 1 0
Telix Pharmaceuticals (Innovations) Pty Limited 2 1 0
Neonc Technologies, Inc. 2 0 0
Lantern Pharma Inc. 2 0 0
NaviFUS Corporation 2 0 0
Oblato, Inc. 1 1 1
NovoCure GmbH 1 1 0
Everfront Biotech Co., Ltd. 1 1 0
Jazz Pharmaceuticals 1 0 1
Laminar Pharmaceuticals 1 1 0
CarThera 1 1 0
Trogenix ltd 1 0 0
NCT07195591 RECRUITING
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
GT Medical Technologies, Inc. n=766
NCT06448286 NOT YET RECRUITING
PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma
Jonsson Comprehensive Cancer Center n=60
NCT05904119 RECRUITING
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
European Organisation for Research and Treatment of Cancer - EORTC n=411
NCT05095376 ACTIVE NOT RECRUITING
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology n=265
NCT06556563 RECRUITING
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NovoCure GmbH n=741
NCT06388733 RECRUITING
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
Ivy Brain Tumor Center n=450
NCT06105619 ACTIVE NOT RECRUITING
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Beijing Pearl Biotechnology Limited Liability Company n=84
NCT07349693 NOT YET RECRUITING
Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Everfront Biotech Co., Ltd. n=175
NCT07100730 RECRUITING
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
Telix Pharmaceuticals (Innovations) Pty Limited n=50
NCT05326464 ACTIVE NOT RECRUITING
Tofacitinib in Recurrent GBM Patients
University of Texas Southwestern Medical Center n=17
NCT04250922 ACTIVE NOT RECRUITING
LAM561 With RT and TMZ for Adults With Glioblastoma
Laminar Pharmaceuticals n=144
NCT05902169 ACTIVE NOT RECRUITING
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
CarThera n=560
NCT02685605 ACTIVE NOT RECRUITING
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
Universitätsmedizin Mannheim n=314
NCT03663725 RECRUITING
Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Centre Oscar Lambret n=486
NCT03970447 RECRUITING
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Global Coalition for Adaptive Research n=1,280
NCT05685004 ACTIVE NOT RECRUITING
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
TVAX Biomedical n=120
NCT07021339 RECRUITING
Anterior Temporal Lobectomy in Temporal Glioblastoma
University Hospital, Bonn n=178
NCT05439278 RECRUITING
Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma
Severance Hospital n=178
NCT06749925 NOT YET RECRUITING
Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma
University of Sao Paulo General Hospital n=186
NCT06419946 NOT YET RECRUITING
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Vastra Gotaland Region n=200
NCT06496971 RECRUITING
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation n=32
NCT05118776 ACTIVE NOT RECRUITING
Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM
Ascletis Pharmaceuticals Co., Ltd. n=136
NCT05271240 RECRUITING
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health n=432
NCT06477939 NOT YET RECRUITING
Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients
Institut de cancérologie Strasbourg Europe n=554
NCT05318612 ACTIVE NOT RECRUITING
Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT)
Radboud University Medical Center n=238
NCT03548571 RECRUITING
Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy
Oslo University Hospital n=60
NCT05100641 NOT YET RECRUITING
AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM
Aivita Biomedical, Inc. n=672
NCT04396860 COMPLETED
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
National Cancer Institute (NCI) n=159
NCT03149575 TERMINATED
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
DelMar Pharmaceuticals, Inc. n=2
NCT03345095 COMPLETED
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
European Organisation for Research and Treatment of Cancer - EORTC n=749
NCT03632135 COMPLETED
Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma
Cordgenics, LLC n=78
NCT03776071 COMPLETED
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Denovo Biopharma LLC n=260
NCT02546102 SUSPENDED
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Precision Life Sciences Group n=234
NCT03149003 COMPLETED
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy
Sumitomo Pharma America, Inc. n=221
NCT02573324 COMPLETED
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
AbbVie n=691
NCT03291977 COMPLETED
Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)
Rennes University Hospital n=51
NCT03393000 TERMINATED
Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Diffusion Pharmaceuticals Inc n=19
NCT04105374 WITHDRAWN
Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma
NRG Oncology
NCT02414165 TERMINATED
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
Tocagen Inc. n=403
NCT02511405 COMPLETED
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Vascular Biogenics Ltd. operating as VBL Therapeutics n=252
NCT07346144 NOT YET RECRUITING
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
Trogenix ltd
NCT03919071 ACTIVE NOT RECRUITING
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
National Cancer Institute (NCI)
NCT03581292 ACTIVE NOT RECRUITING
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
National Cancer Institute (NCI)
NCT04145115 ACTIVE NOT RECRUITING
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
National Cancer Institute (NCI)
NCT05843253 RECRUITING
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
NCT07416188 NOT YET RECRUITING
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institute of Neurological Disorders and Stroke (NINDS)
NCT05607407 RECRUITING
Methimazole in Patients With Progressive Glioblastoma
Case Comprehensive Cancer Center
NCT06325683 RECRUITING
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT05463848 RECRUITING
Surgical Pembro +/- Olaparib w TMZ for rGBM
L. Nicolas Gonzalez Castro, MD, PhD
NCT06319027 RECRUITING
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
ECOG-ACRIN Cancer Research Group
NCT02704858 RECRUITING
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Neonc Technologies, Inc.
NCT06047379 RECRUITING
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
NCT07439172 NOT YET RECRUITING
Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.
The Cooper Health System
NCT06672575 RECRUITING
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
M.D. Anderson Cancer Center
NCT05765812 RECRUITING
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debiopharm International SA
NCT02455557 ACTIVE NOT RECRUITING
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Roswell Park Cancer Institute
NCT07431216 NOT YET RECRUITING
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression
Lantern Pharma Inc.
NCT06058988 RECRUITING
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Memorial Sloan Kettering Cancer Center
NCT05969860 RECRUITING
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
NCT06805305 RECRUITING
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Diakonos Oncology Corporation
NCT06622434 RECRUITING
New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study
Assistance Publique - Hôpitaux de Paris
NCT03212274 ACTIVE NOT RECRUITING
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
National Cancer Institute (NCI)
NCT07410676 RECRUITING
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Essen Biotech
NCT07318818 RECRUITING
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
Tasly Pharmaceutical Group Co., Ltd
NCT07410494 RECRUITING
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Essen Biotech
NCT04765514 RECRUITING
Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients
AHS Cancer Control Alberta
NCT07263438 RECRUITING
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial
Centre Hospitalier Universitaire Vaudois
NCT07326566 NOT YET RECRUITING
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
NCT06061809 RECRUITING
N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
ImmunityBio, Inc.
NCT07386002 NOT YET RECRUITING
The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
T-MAXIMUM Pharmaceutical Inc
NCT04485949 ACTIVE NOT RECRUITING
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma
Imvax
NCT04478279 ACTIVE NOT RECRUITING
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
NCT03866109 ACTIVE NOT RECRUITING
A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
Genenta Science
NCT07392957 NOT YET RECRUITING
Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma
Washington University School of Medicine
NCT03405792 ACTIVE NOT RECRUITING
Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)
University of Florida
NCT07391215 RECRUITING
5G-PEARL: Paxalisib in Malignant Brain Tumours
Institute of Cancer Research, United Kingdom
NCT05635734 ACTIVE NOT RECRUITING
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
Cantex Pharmaceuticals
NCT07225621 RECRUITING
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Alpheus Medical, Inc.
NCT07389278 NOT YET RECRUITING
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
Sabine Mueller, MD, PhD
NCT05653622 RECRUITING
Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma
Centre Paul Strauss
NCT05653635 RECRUITING
Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study
Centre Paul Strauss
NCT05781321 ACTIVE NOT RECRUITING
Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study
Mayo Clinic
NCT06810544 RECRUITING
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
NCT05683808 RECRUITING
Venous Thromboembolism Prevention in Outpatients With Glioma
University of Vermont Medical Center
NCT05629702 RECRUITING
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
University of Birmingham
NCT07297212 RECRUITING
A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
NCT03491683 ACTIVE NOT RECRUITING
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
NCT06926075 RECRUITING
Early Phase Study of Kesonotide in Participants With Solid Tumours
Filamon LTD
NCT07365280 NOT YET RECRUITING
Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma
ZSky Biotech Inc
NCT04752813 ACTIVE NOT RECRUITING
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
BPGbio
NCT07356973 NOT YET RECRUITING
Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma
CRISM Therapeutics LTD
NCT07364786 RECRUITING
Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma
Peter Siesjö
NCT05084430 RECRUITING
Study of Pembrolizumab and M032 (NSC 733972)
University of Alabama at Birmingham
NCT06630260 RECRUITING
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Institute of Cancer Research, United Kingdom
NCT07347210 NOT YET RECRUITING
Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma
Centre Hospitalier Universitaire de Besancon
NCT04623931 RECRUITING
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
M.D. Anderson Cancer Center
NCT02586857 ACTIVE NOT RECRUITING
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Acerta Pharma BV
NCT05465954 RECRUITING
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Mayo Clinic
NCT06816927 RECRUITING
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
Duke University
NCT05871021 RECRUITING
Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
University Hospital Tuebingen
NCT03277638 ACTIVE NOT RECRUITING
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
Case Comprehensive Cancer Center
NCT04049669 ACTIVE NOT RECRUITING
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Theodore S. Johnson
NCT03743662 ACTIVE NOT RECRUITING
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
Memorial Sloan Kettering Cancer Center
NCT06558214 RECRUITING
OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial
University of Florida
NCT07093814 RECRUITING
A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Guangzhou Virotech Pharmaceutical Co., Ltd.
NCT05879250 RECRUITING
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
NCT06991101 RECRUITING
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Baptist Health South Florida
NCT05708352 RECRUITING
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
Cedars-Sinai Medical Center
NCT04817254 ACTIVE NOT RECRUITING
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Cancer Institute (NCI)
NCT07285044 RECRUITING
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT04116411 ACTIVE NOT RECRUITING
A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
Cecilia Soderberg-Naucler
NCT04691960 ACTIVE NOT RECRUITING
A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging
Weill Medical College of Cornell University
NCT05039281 RECRUITING
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
M.D. Anderson Cancer Center
NCT02344355 ACTIVE NOT RECRUITING
A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Bryan Allen
NCT05956821 RECRUITING
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
University of Miami
NCT03718767 ACTIVE NOT RECRUITING
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
National Cancer Institute (NCI)
NCT04945148 RECRUITING
Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide
Hopital Foch
NCT03233152 ACTIVE NOT RECRUITING
A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.
Universitair Ziekenhuis Brussel
NCT06521567 ACTIVE NOT RECRUITING
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
GlaxoSmithKline
NCT02977780 RECRUITING
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Patrick Wen, MD
NCT06069726 RECRUITING
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Duke University
NCT04373785 NOT YET RECRUITING
NG101m Adjuvant Therapy in Glioblastoma Patients
NeuGATE Theranostics
NCT04729959 ACTIVE NOT RECRUITING
Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT04574856 ACTIVE NOT RECRUITING
Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma
University of Michigan Rogel Cancer Center
NCT06814496 RECRUITING
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT03862430 ACTIVE NOT RECRUITING
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
NuvOx LLC
NCT06059690 RECRUITING
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
Jonsson Comprehensive Cancer Center
NCT05864534 RECRUITING
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Northwestern University
NCT06011109 RECRUITING
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Aveta Biomics, Inc.
NCT06804655 NOT YET RECRUITING
Pharmacoscopy for Patients With Refractory Primary Brain Tumors
University of Zurich
NCT07193654 RECRUITING
Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06649851 RECRUITING
G-CSF After Chemo-radiation in Patients With Glioblastoma
Massachusetts General Hospital
NCT06835803 RECRUITING
Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial
Brigham and Women's Hospital
NCT07180927 RECRUITING
DLL3 CAR-T Therapy Targeting Brain Tumors
Shenzhen Geno-Immune Medical Institute
NCT06492486 NOT YET RECRUITING
Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow
Tata Memorial Centre
NCT05736406 RECRUITING
A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
Hemerion Therapeutics
NCT06102525 RECRUITING
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma
Rznomics, Inc.
NCT04977375 RECRUITING
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Chirag G. Patil
NCT02981940 ACTIVE NOT RECRUITING
A Study of Abemaciclib in Recurrent Glioblastoma
Dana-Farber Cancer Institute
NCT06504381 RECRUITING
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
University of California, San Francisco
NCT05120284 ACTIVE NOT RECRUITING
Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
University of Florida
NCT04863950 RECRUITING
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
NCT04587830 ACTIVE NOT RECRUITING
ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme
Polaris Group
NCT07138001 NOT YET RECRUITING
Phase 2 Clinical Trial of KH617
Sichuan Honghe Biotechnology Co., Ltd.
NCT04747145 ACTIVE NOT RECRUITING
Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma
Medical College of Wisconsin
NCT06018363 RECRUITING
Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection
Dushu Lake Hospital Affiliated to Soochow University
NCT07130149 ENROLLING BY INVITATION
Sonodynamic-Chemoradiotherapy Integration in Glioblastoma
Yingjuan Zheng
NCT04910022 ACTIVE NOT RECRUITING
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Nerviano Medical Sciences
NCT04225039 ACTIVE NOT RECRUITING
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
University of Pennsylvania
NCT02337686 ACTIVE NOT RECRUITING
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
M.D. Anderson Cancer Center
NCT07003542 RECRUITING
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
Case Comprehensive Cancer Center
NCT04469075 ACTIVE NOT RECRUITING
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
Memorial Sloan Kettering Cancer Center
NCT06356883 RECRUITING
Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
Université de Sherbrooke
NCT04559230 RECRUITING
Sacituzumab Govitecan in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
NCT02974621 ACTIVE NOT RECRUITING
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT04528680 ACTIVE NOT RECRUITING
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Northwestern University
NCT05929495 RECRUITING
Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
University of Milano Bicocca
NCT05909618 RECRUITING
Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases
Sheba Medical Center
NCT04523688 RECRUITING
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT07047066 NOT YET RECRUITING
A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma
Tongji Hospital
NCT03175224 RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Apollomics Inc.
NCT02780024 ACTIVE NOT RECRUITING
Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM
McGill University Health Centre/Research Institute of the McGill University Health Centre
NCT04765098 RECRUITING
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients
AHS Cancer Control Alberta
NCT04121455 ACTIVE NOT RECRUITING
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
TME Pharma AG
NCT04019262 ACTIVE NOT RECRUITING
Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma
John Flickinger
NCT01777919 NOT YET RECRUITING
Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform
Olympion Medical Center
NCT02331498 RECRUITING
Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Centre Antoine Lacassagne
NCT03673787 ACTIVE NOT RECRUITING
A Trial of Ipatasertib in Combination With Atezolizumab
Institute of Cancer Research, United Kingdom
NCT03897491 ACTIVE NOT RECRUITING
PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
photonamic GmbH & Co. KG
NCT06598787 RECRUITING
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
Sichuan Baili Pharmaceutical Co., Ltd.
NCT04762069 ACTIVE NOT RECRUITING
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
CNS Pharmaceuticals, Inc.
NCT05664243 ACTIVE NOT RECRUITING
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
In8bio Inc.
NCT06936046 RECRUITING
Enhanced Adjuvant Therapy for Newly Diagnosed GBM With Partial Surgical Resection or Short-term Progression
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT04922723 ACTIVE NOT RECRUITING
Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma
West Virginia University
NCT03688178 ACTIVE NOT RECRUITING
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
Annick Desjardins, MD
NCT06016452 RECRUITING
A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma
Tata Memorial Centre
NCT02800486 RECRUITING
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
NCT02861898 RECRUITING
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Northwell Health
NCT06687681 RECRUITING
Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Marzieh Ebrahimi
NCT03213002 RECRUITING
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Northwell Health
NCT06894225 NOT YET RECRUITING
Proof-of-Concept Study of ACT001 in Adult Patients With Recurrent Glioblastoma Harbouring STAT3-High Signature
National Neuroscience Institute
NCT03197506 ACTIVE NOT RECRUITING
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Mayo Clinic
NCT06690216 ENROLLING BY INVITATION
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
Man Hu
NCT03382977 RECRUITING
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
VBI Vaccines Inc.
NCT03452579 ACTIVE NOT RECRUITING
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
David Peereboom
NCT04590664 RECRUITING
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Emory University
NCT04881032 ACTIVE NOT RECRUITING
AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma
Centre Jean Perrin
NCT06336291 RECRUITING
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
Philogen S.p.A.
NCT06780592 NOT YET RECRUITING
Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery
Huashan Hospital
NCT05590689 RECRUITING
Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor
Universität Münster
NCT04195139 ACTIVE NOT RECRUITING
Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM
University of Sydney
NCT03395587 ACTIVE NOT RECRUITING
Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma
Heinrich-Heine University, Duesseldorf
NCT05565521 RECRUITING
UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly
Sunnybrook Health Sciences Centre
NCT05768919 RECRUITING
Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
SignPath Pharma, Inc.
NCT03596086 RECRUITING
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
David Baskin MD
NCT03603405 RECRUITING
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
The Methodist Hospital Research Institute
NCT06160206 RECRUITING
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Academic and Community Cancer Research United
NCT06640582 RECRUITING
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
Essen Biotech
NCT04267978 RECRUITING
Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas
Beijing Sanbo Brain Hospital
NCT04913337 ACTIVE NOT RECRUITING
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
NCT04115761 RECRUITING
Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients
Ever Supreme Bio Technology Co., Ltd.
NCT02649582 ACTIVE NOT RECRUITING
Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients
University Hospital, Antwerp
NCT06595186 RECRUITING
JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)
JenKem Technology Co., Ltd.
NCT05986851 ACTIVE NOT RECRUITING
Azeliragon in MGMT Unmethylated Glioblastoma
Cantex Pharmaceuticals
NCT06353360 RECRUITING
TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
NCT06157541 RECRUITING
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
Queensland Institute of Medical Research
NCT03899857 ACTIVE NOT RECRUITING
Pembrolizumab for Newly Diagnosed Glioblastoma
University of Zurich
NCT04600817 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
TJ Biopharma Co., Ltd.
NCT04573192 RECRUITING
A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
Philogen S.p.A.
NCT06329570 NOT YET RECRUITING
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
NCT06327451 RECRUITING
Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma
Tianjin Medical University General Hospital
NCT06297512 RECRUITING
Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM).
Iacopo Sardi
NCT06220552 RECRUITING
The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma
Fifth Affiliated Hospital, Sun Yat-Sen University
NCT06218524 NOT YET RECRUITING
The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM
Southern Medical University, China
NCT05820191 NOT YET RECRUITING
B-amyloid as a Marker for GBM Bioimaging
Universidad Central del Caribe
NCT04443010 RECRUITING
Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Philogen S.p.A.
NCT05540275 NOT YET RECRUITING
Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
Henan Provincial People's Hospital
NCT05842746 NOT YET RECRUITING
Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma
Peking Union Medical College Hospital
NCT05502991 NOT YET RECRUITING
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
Henan Provincial People's Hospital
NCT05432804 SUSPENDED
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
National Cancer Institute (NCI)
NCT02942264 TERMINATED
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Cancer Institute (NCI)
NCT03529448 COMPLETED
TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma
Grupo Español de Investigación en Neurooncología
NCT04482933 WITHDRAWN
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
Pediatric Brain Tumor Consortium
NCT07301268 SUSPENDED
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
NCT04417088 COMPLETED
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
InSightec
NCT04440358 COMPLETED
Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM
InSightec
NCT02617745 COMPLETED
Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid
Centre Henri Becquerel
NCT05267106 TERMINATED
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
Incyte Corporation
NCT05183204 SUSPENDED
Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
Weill Medical College of Cornell University
NCT06359379 TERMINATED
Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
Shuttle Pharmaceuticals, Inc.
NCT04391062 COMPLETED
Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma
University Hospital, Lille
NCT04116658 COMPLETED
First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma
Enterome
NCT03532295 COMPLETED
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Washington University School of Medicine
NCT03797326 COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
Merck Sharp & Dohme LLC
NCT03746080 COMPLETED
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Lawrence D Recht
NCT06855628 SUSPENDED
Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)
Stanford University
NCT03868943 TERMINATED
Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma
Wake Forest University Health Sciences
NCT06439420 COMPLETED
CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial
Virginia Commonwealth University
NCT05608395 COMPLETED
11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)
Masaryk Memorial Cancer Institute
NCT03174197 COMPLETED
Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
M.D. Anderson Cancer Center
NCT03347617 TERMINATED
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
OHSU Knight Cancer Institute
NCT03050736 COMPLETED
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
Kintara Therapeutics, Inc.
NCT02717962 COMPLETED
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Kintara Therapeutics, Inc.
NCT03475186 COMPLETED
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Wake Forest University Health Sciences
NCT07120620 COMPLETED
PriCoTTF Study: TTFields Before and During Radiotherapy for Newly Diagnosed Glioblastoma
Sied Kebir
NCT04388475 COMPLETED
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Oblato, Inc.
NCT01931098 COMPLETED
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Cancer Institute (NCI)
NCT03018288 TERMINATED
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
National Cancer Institute (NCI)
NCT03137888 COMPLETED
Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
Emory University
NCT05563272 TERMINATED
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
Telix Pharmaceuticals (Innovations) Pty Ltd
NCT02611024 COMPLETED
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
NCT03778294 COMPLETED
18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy
Mayo Clinic
NCT02781792 COMPLETED
Temozolomide Chronotherapy for High Grade Glioma
Washington University School of Medicine
NCT04740190 COMPLETED
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd
The University of Hong Kong
NCT04406272 TERMINATED
VB-111 in Surgically Accessible Recurrent/Progressive GBM
Dana-Farber Cancer Institute
NCT02655601 COMPLETED
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
BioMimetix JV, LLC
NCT04051606 COMPLETED
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Case Comprehensive Cancer Center
NCT02866747 COMPLETED
A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma
Institut Claudius Regaud
NCT04479241 COMPLETED
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Istari Oncology, Inc.
NCT03047473 COMPLETED
Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
Clinique Neuro-Outaouais
NCT03782415 COMPLETED
Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
MediciNova
NCT03665545 COMPLETED
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
University Hospital, Geneva
NCT04006119 TERMINATED
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
Alaunos Therapeutics
NCT02715609 COMPLETED
Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Washington University School of Medicine
NCT05753007 TERMINATED
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
NCT03522298 COMPLETED
Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Kazia Therapeutics Limited
NCT04469699 TERMINATED
Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma
University Hospital Muenster
NCT05737212 TERMINATED
Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas
Dawonmedax Co., Ltd.
NCT02465268 COMPLETED
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
University of Florida
NCT03914742 COMPLETED
BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04280848 COMPLETED
Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma
Centre Hospitalier Universitaire de Besancon
NCT06328036 WITHDRAWN
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT04421378 TERMINATED
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
NCT05973903 WITHDRAWN
Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
Tel Aviv Medical Center
NCT05879120 WITHDRAWN
Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
M.D. Anderson Cancer Center
NCT04845919 COMPLETED
Sonodynamic Therapy with ExAblate System in Glioblastoma Patients
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
NCT03732352 COMPLETED
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
NCT02372409 TERMINATED
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
Washington University School of Medicine
NCT03973918 TERMINATED
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04952571 TERMINATED
Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)
Beijing Sanbo Brain Hospital
NCT03363659 TERMINATED
Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme
Wake Forest University Health Sciences
NCT03879512 COMPLETED
Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG
Wuerzburg University Hospital
NCT03661723 COMPLETED
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Dana-Farber Cancer Institute
NCT03234595 COMPLETED
A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
Everfront Biotech Co., Ltd.
NCT04013672 COMPLETED
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
David Peereboom
NCT06562621 COMPLETED
Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma
Beijing Neurosurgical Institute
NCT04492163 COMPLETED
Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM
NovoCure GmbH
NCT05370508 TERMINATED
A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM
SonALAsense, Inc.
NCT04915404 TERMINATED
Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)
WPD Pharmaceuticals Sp. z o.o.
NCT03139916 COMPLETED
Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
Massachusetts General Hospital
NCT05074992 TERMINATED
A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma
University College, London
NCT04681677 TERMINATED
Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
Xoft, Inc.
NCT03927222 TERMINATED
Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
NCT03466450 COMPLETED
Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma
Grupo Español de Investigación en Neurooncología
NCT02684058 COMPLETED
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Novartis Pharmaceuticals
NCT04629209 WITHDRAWN
A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma
Masonic Cancer Center, University of Minnesota
NCT03027388 COMPLETED
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT03684811 COMPLETED
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Forma Therapeutics, Inc.
NCT02432417 WITHDRAWN
The Addition of Chloroquine to Chemoradiation for Glioblastoma,
Maastricht Radiation Oncology
NCT02315534 COMPLETED
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
Sumitomo Pharma America, Inc.
NCT03463265 COMPLETED
Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
Aadi Bioscience, Inc.
NCT04119674 COMPLETED
Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma
Zhejiang Cancer Hospital
NCT02330991 COMPLETED
A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse
Beijing Sanbo Brain Hospital
NCT02661282 COMPLETED
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
M.D. Anderson Cancer Center
NCT02366728 COMPLETED
DC Migration Study for Newly-Diagnosed GBM
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
NCT04933942 WITHDRAWN
Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma
European Organisation for Research and Treatment of Cancer - EORTC
NCT03618667 COMPLETED
GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
Samsung Medical Center
NCT03849105 COMPLETED
131I-IPA and Concurrent XRT in Recurrent GBM
Telix Pharmaceuticals (Innovations) Pty Limited
NCT05218408 WITHDRAWN
CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
Celularity Incorporated
NCT03430791 TERMINATED
Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Baptist Health South Florida
NCT04657315 COMPLETED
Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients
CHA University
NCT04444427 COMPLETED
Evaluation of GLR2007 for Advanced Solid Tumors
Gan and Lee Pharmaceuticals, USA
NCT03119064 TERMINATED
BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
Brown University
NCT02858895 COMPLETED
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Medicenna Therapeutics, Inc.
NCT02336165 COMPLETED
Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
Ludwig Institute for Cancer Research
NCT03649464 WITHDRAWN
Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
Oblato, Inc.
NCT02885324 TERMINATED
Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
Indiana University
NCT03744026 COMPLETED
Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9
CarThera
NCT03856099 TERMINATED
TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab
PharmAbcine
NCT03022578 TERMINATED
Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
M.D. Anderson Cancer Center
NCT03367715 COMPLETED
Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
NYU Langone Health
NCT02968940 COMPLETED
Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma
NYU Langone Health
NCT02663271 TERMINATED
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
University of Florida
NCT02330562 COMPLETED
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Celgene
NCT03216499 COMPLETED
HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02794883 COMPLETED
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
Northwestern University
NCT02750891 COMPLETED
A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas
Sumitomo Pharma Co., Ltd.
NCT04065087 WITHDRAWN
Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma
Genexine, Inc.
NCT02770378 COMPLETED
A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
University of Ulm
NCT02844439 COMPLETED
Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Kadmon Corporation, LLC
NCT03034135 COMPLETED
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
Cantex Pharmaceuticals
NCT03243851 COMPLETED
Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma
Yong-Kil Hong
NCT02765165 TERMINATED
Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Proximagen, LLC
NCT02798406 COMPLETED
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
DNAtrix, Inc.
NCT02743078 TERMINATED
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
RTOG Foundation, Inc.
NCT02758366 TERMINATED
Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma
Meyer Children's Hospital IRCCS
NCT03033524 COMPLETED
Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma
PharmAbcine
NCT02709889 TERMINATED
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
AbbVie
NCT03506139 WITHDRAWN
Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma
John M. Buatti
NCT03014804 WITHDRAWN
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
NCT02626364 COMPLETED
Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Arog Pharmaceuticals, Inc.
NCT02343406 COMPLETED
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas
AbbVie
NCT02799238 COMPLETED
Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma
CytoVac A/S
NCT02342379 COMPLETED
TH-302 in Combination With Bevacizumab for Glioblastoma
The University of Texas Health Science Center at San Antonio
NCT02754362 WITHDRAWN
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NYU Langone Health
NCT02335918 COMPLETED
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Celldex Therapeutics
NCT02364206 COMPLETED
Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma
Centre Jean Perrin
NCT02395692 TERMINATED
Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT03291314 COMPLETED
Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
Universitair Ziekenhuis Brussel
NCT02850744 TERMINATED
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
PIQUR Therapeutics AG
NCT02698280 COMPLETED
Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma
Huashan Hospital
NCT02478164 COMPLETED
Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
Dana-Farber Cancer Institute
NCT02654041 TERMINATED
Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients
Musli Thyropeutics Ltd.
NCT01788280 WITHDRAWN
Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab
University of Utah
NCT02348255 WITHDRAWN
NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
University of California, Davis
NCT02550249 COMPLETED
Neoadjuvant Nivolumab in Glioblastoma
Clinica Universidad de Navarra, Universidad de Navarra
NCT02394665 TERMINATED
Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma
University of Miami
NCT01445691 WITHDRAWN
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
Constantinos Hadjipanayis
NCT02521090 WITHDRAWN
EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma
Barbara Ann Karmanos Cancer Institute
NCT03152318 ACTIVE NOT RECRUITING
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Dana-Farber Cancer Institute
NCT07422363 NOT YET RECRUITING
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT06860594 RECRUITING
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
National Cancer Institute (NCI)
NCT05303467 RECRUITING
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Boston Scientific Corporation
NCT04732065 RECRUITING
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Sabine Mueller, MD, PhD
NCT04661384 ACTIVE NOT RECRUITING
Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma
City of Hope Medical Center
NCT03389802 ACTIVE NOT RECRUITING
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
Pediatric Brain Tumor Consortium
NCT07422896 NOT YET RECRUITING
A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma
Catalina Lee Chang
NCT03514069 ACTIVE NOT RECRUITING
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
Case Comprehensive Cancer Center
NCT06934889 RECRUITING
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Memorial Sloan Kettering Cancer Center
NCT03911388 RECRUITING
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
NCT04678648 RECRUITING
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
NCT05565118 RECRUITING
Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
Case Comprehensive Cancer Center
NCT04606316 ACTIVE NOT RECRUITING
Surgical Nivolumab And Ipilimumab For Recurrent GBM
Patrick Wen, MD
NCT07218367 NOT YET RECRUITING
Phase I Trial of pH Resections of GBM at VA
VA Office of Research and Development
NCT04197934 ACTIVE NOT RECRUITING
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Mayo Clinic
NCT06186401 RECRUITING
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
Hideho Okada, MD, PhD
NCT04015700 ACTIVE NOT RECRUITING
Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
NCT05109728 ACTIVE NOT RECRUITING
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
Novartis Pharmaceuticals
NCT03389230 ACTIVE NOT RECRUITING
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
City of Hope Medical Center
NCT07385846 NOT YET RECRUITING
Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency
Jennifer Leddon
NCT05739942 ACTIVE NOT RECRUITING
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
Novartis Pharmaceuticals
NCT05627323 ACTIVE NOT RECRUITING
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
Chimeric Therapeutics
NCT06815432 RECRUITING
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
Baylor College of Medicine
NCT06344130 RECRUITING
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT04216329 ACTIVE NOT RECRUITING
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
NCT07143812 RECRUITING
A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma
CHA University
NCT05450744 RECRUITING
131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)
Telix Pharmaceuticals (Innovations) Pty Limited
NCT07343986 RECRUITING
Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma
University of Virginia
NCT05835687 RECRUITING
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
St. Jude Children's Research Hospital
NCT05283330 RECRUITING
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
NCT05236036 ACTIVE NOT RECRUITING
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
Northwestern University
NCT05083754 RECRUITING
Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05106296 RECRUITING
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Theodore S. Johnson
NCT04573140 RECRUITING
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
University of Florida
NCT05353530 RECRUITING
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
University of Florida
NCT06389591 RECRUITING
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
University of Florida
NCT03423628 RECRUITING
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
AstraZeneca
NCT06894979 RECRUITING
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
NCT06410248 ACTIVE NOT RECRUITING
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Northwestern University
NCT04541082 RECRUITING
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
NCT03749187 ACTIVE NOT RECRUITING
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
University of California, San Francisco
NCT05686798 RECRUITING
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Henry Ford Health System
NCT07209241 RECRUITING
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
University of Pennsylvania
NCT05743595 RECRUITING
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
NCT03587038 ACTIVE NOT RECRUITING
OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
University of Oklahoma
NCT04900792 ACTIVE NOT RECRUITING
A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
Bryan Allen
NCT07089641 RECRUITING
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
Jonsson Comprehensive Cancer Center
NCT07193628 RECRUITING
B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT02192359 ACTIVE NOT RECRUITING
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
NCT07223034 RECRUITING
A Study of 177Lu-PSMA-617 in People With Gliomas
Memorial Sloan Kettering Cancer Center
NCT04903795 NOT YET RECRUITING
BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
NCT04319276 ACTIVE NOT RECRUITING
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
Medical College of Wisconsin
NCT04555577 RECRUITING
Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
NCT05789394 RECRUITING
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
Mayo Clinic
NCT05139056 RECRUITING
Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
City of Hope Medical Center
NCT05366179 RECRUITING
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
UNC Lineberger Comprehensive Cancer Center
NCT07145112 RECRUITING
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
University of California, Davis
NCT03451799 ACTIVE NOT RECRUITING
Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma
Jethro Hu
NCT04214392 ACTIVE NOT RECRUITING
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
City of Hope Medical Center
NCT05168423 ACTIVE NOT RECRUITING
CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM
University of Pennsylvania
NCT03535350 ACTIVE NOT RECRUITING
Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Case Comprehensive Cancer Center
NCT07185880 NOT YET RECRUITING
A Phase 1 Study of the Safety and Tolerability of MT-125 in GBM Patients
Myosin Therapeutics Inc.
NCT05557292 RECRUITING
RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
Nicholas Butowski
NCT07179328 RECRUITING
Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy
Sunnybrook Health Sciences Centre
NCT07141732 RECRUITING
Combined Treatment of Patients With Newly Diagnosed Glioblastoma Using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System for Intraoperative Balloon Electronic Brachytherapy
Joint Stock Company European Medical Centre
NCT03896568 RECRUITING
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
M.D. Anderson Cancer Center
NCT03961971 ACTIVE NOT RECRUITING
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03223103 ACTIVE NOT RECRUITING
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
Adilia Hormigo
NCT02208362 ACTIVE NOT RECRUITING
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
City of Hope Medical Center
NCT04978727 ACTIVE NOT RECRUITING
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Pediatric Brain Tumor Consortium
NCT04201873 ACTIVE NOT RECRUITING
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
NCT07134842 RECRUITING
A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.
University College, London
NCT05222802 ACTIVE NOT RECRUITING
A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
Katmai Pharmaceuticals Inc.
NCT06455189 NOT YET RECRUITING
Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas
Case Comprehensive Cancer Center
NCT06176066 RECRUITING
PH Sensitive MRI Based Resections of Glioblastoma
University of California, Los Angeles
NCT05917145 RECRUITING
ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma
Mayo Clinic
NCT06614855 ACTIVE NOT RECRUITING
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
James Markert, MD
NCT03657576 ACTIVE NOT RECRUITING
Trial of C134 in Patients With Recurrent GBM
University of Alabama at Birmingham
NCT06973096 RECRUITING
CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy
University of Pennsylvania
NCT02974738 ACTIVE NOT RECRUITING
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT04003649 RECRUITING
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
City of Hope Medical Center
NCT06773481 RECRUITING
BC008-1A Injection for Recurrent CNS WHO G4 Glioma
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
NCT04047706 ACTIVE NOT RECRUITING
Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
NCT04477200 ACTIVE NOT RECRUITING
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
University of Michigan Rogel Cancer Center
NCT06896110 ENROLLING BY INVITATION
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
Andrew P. Groves
NCT06815029 RECRUITING
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
City of Hope Medical Center
NCT05879367 RECRUITING
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Orbus Therapeutics, Inc.
NCT06902350 RECRUITING
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
Chipscreen Biosciences, Ltd.
NCT05698524 RECRUITING
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
NCT04323046 RECRUITING
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
Sabine Mueller, MD, PhD
NCT06632236 RECRUITING
5G-EMERALD: Amivantamab in Malignant Brain Tumours
Institute of Cancer Research, United Kingdom
NCT05495295 RECRUITING
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
Phost'In Therapeutics
NCT05769660 RECRUITING
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)
BeyondBio Inc.
NCT05241392 ACTIVE NOT RECRUITING
Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma
Beijing Tiantan Hospital
NCT04968366 ACTIVE NOT RECRUITING
Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery
Beijing Tiantan Hospital
NCT06097975 RECRUITING
A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma
Universitair Ziekenhuis Brussel
NCT03170141 ENROLLING BY INVITATION
Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
Shenzhen Geno-Immune Medical Institute
NCT05698199 ACTIVE NOT RECRUITING
Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)
Immunomic Therapeutics, Inc.
NCT04019002 ACTIVE NOT RECRUITING
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
Susan Chang
NCT05561374 ACTIVE NOT RECRUITING
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
Oblato, Inc.
NCT06585527 RECRUITING
Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma
Beijing Neurosurgical Institute
NCT06650605 RECRUITING
Phase 1 Open-label Study of 123I-ATT001 in Subjects with Relapsed Glioblastoma
Theragnostics Ltd
NCT06616727 ENROLLING BY INVITATION
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
Shanghai Simnova Biotechnology Co.,Ltd.
NCT04933422 NOT YET RECRUITING
CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)
Crimson Biopharm Inc.
NCT06524063 NOT YET RECRUITING
Targeted Survivin DC Cell Injection for the Treatment of GBM
Beijing Tricision Biotherapeutics Inc
NCT06418113 RECRUITING
Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma
Hospital San Carlos, Madrid
NCT03383978 ACTIVE NOT RECRUITING
Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma
Johann Wolfgang Goethe University Hospital
NCT06132438 NOT YET RECRUITING
Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma
Charlotte Lemech
NCT05363826 RECRUITING
Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®
Photolitec LLC
NCT05095441 NOT YET RECRUITING
A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma
ImmVira Pharma Co. Ltd
NCT06665724 COMPLETED
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
Universität Münster
NCT02669173 COMPLETED
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
NCT05938387 COMPLETED
Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma
CureVac
NCT03681028 COMPLETED
Feasibility of Individualized Therapy for Recurrent Glioblastoma
Jennifer Clarke
NCT06193174 TERMINATED
Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
University of Alabama at Birmingham
NCT06095375 COMPLETED
Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients
Istituto Oncologico Veneto IRCCS
NCT04295759 COMPLETED
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Pediatric Brain Tumor Consortium
NCT02709226 COMPLETED
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT04474353 COMPLETED
Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma
Stanford University
NCT05977322 TERMINATED
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
Novartis Pharmaceuticals
NCT03224104 COMPLETED
Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
European Organisation for Research and Treatment of Cancer - EORTC
NCT06806228 SUSPENDED
Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)
Petrov, Andrey
NCT03107780 TERMINATED
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
National Cancer Institute (NCI)
NCT05341947 WITHDRAWN
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
Jeremy Rudnick, M.D
NCT04982926 TERMINATED
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Taiho Oncology, Inc.
NCT03426891 COMPLETED
Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
NCT03679754 COMPLETED
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
Alaunos Therapeutics
NCT05376800 COMPLETED
A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma
Boehringer Ingelheim
NCT03636477 COMPLETED
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
Alaunos Therapeutics
NCT04963413 TERMINATED
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.
University of Florida
NCT06501911 WITHDRAWN
A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma
University of Nebraska
NCT03452930 COMPLETED
Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
M.D. Anderson Cancer Center
NCT02766699 COMPLETED
A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM
Engeneic Pty Limited
NCT05187624 COMPLETED
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
Hoffmann-La Roche
NCT02186509 COMPLETED
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT02026271 COMPLETED
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
Alaunos Therapeutics
NCT04222309 SUSPENDED
Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)
Northwell Health
NCT02722512 TERMINATED
Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine
Ann & Robert H Lurie Children's Hospital of Chicago
NCT05324501 TERMINATED
A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
Biodexa Pharmaceuticals
NCT04397679 TERMINATED
Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma
Barbara Ann Karmanos Cancer Institute
NCT02323880 COMPLETED
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Children's Oncology Group
NCT04842513 COMPLETED
Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma
University Hospital Tuebingen
NCT03232424 COMPLETED
NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
Hackensack Meridian Health
NCT02101905 COMPLETED
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
National Cancer Institute (NCI)
NCT05773664 WITHDRAWN
Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma
City of Hope Medical Center
NCT03539731 TERMINATED
[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers
Guido A. Davidzon, MD, SM
NCT04324840 TERMINATED
A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma
Celgene
NCT03493932 COMPLETED
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
National Institute of Neurological Disorders and Stroke (NINDS)
NCT04047303 TERMINATED
CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
Celgene
NCT05538572 COMPLETED
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Prelude Therapeutics
NCT03250299 TERMINATED
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Basilea Pharmaceutica
NCT03434262 COMPLETED
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
St. Jude Children's Research Hospital
NCT03043391 COMPLETED
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Istari Oncology, Inc.
NCT05304663 WITHDRAWN
Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression
Philogen S.p.A.
NCT05666349 WITHDRAWN
Reirradiation and Niraparib in Patients With Recurrent Glioblastoma
University College, London
NCT03705351 TERMINATED
Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
Providence Health & Services
NCT02869243 COMPLETED
A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients
Stemgen
NCT02457845 COMPLETED
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
Gregory K. Friedman, MD
NCT04552886 COMPLETED
Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma
The Cooper Health System
NCT02530502 TERMINATED
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
NCT02498665 COMPLETED
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
NCT02833701 TERMINATED
Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
University of Nebraska
NCT03971734 TERMINATED
Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02658981 COMPLETED
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02386826 COMPLETED
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
SCRI Development Innovations, LLC
NCT04608812 TERMINATED
Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
OncoSynergy, Inc.
NCT02619864 COMPLETED
mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme
Canadian Cancer Trials Group
NCT04541225 TERMINATED
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Nuvation Bio Inc.
NCT03332355 TERMINATED
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
Vanquish Oncology, Inc.
NCT02444546 COMPLETED
Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
Mayo Clinic
NCT04716699 COMPLETED
Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma
Kiarash Shahlaie, M.D., Ph.D.
NCT03714334 TERMINATED
DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma
Clinica Universidad de Navarra, Universidad de Navarra
NCT04205357 COMPLETED
Sulfasalazine and Stereotactic Radiosurgery for Recurrent Glioblastoma
Haukeland University Hospital
NCT03867123 COMPLETED
A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients
Laminar Pharmaceuticals
NCT02664363 TERMINATED
EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
Daniel Landi
NCT03072134 COMPLETED
Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Northwestern University
NCT03355794 COMPLETED
A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
Children's Hospital Medical Center, Cincinnati
NCT02311920 COMPLETED
Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Cancer Institute (NCI)
NCT04782609 TERMINATED
Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma
Samus Therapeutics, Inc.
NCT04200066 WITHDRAWN
A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
University of Rochester
NCT04489420 TERMINATED
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Celularity Incorporated
NCT05476341 COMPLETED
A Phase I Clinical Trial of Bevacizumab Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NCT02644291 COMPLETED
Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02864368 TERMINATED
Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
Eric Thompson, M.D.
NCT02808364 COMPLETED
Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)
Guangdong 999 Brain Hospital
NCT02709616 COMPLETED
Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)
Guangdong 999 Brain Hospital
NCT02871843 COMPLETED
RRx-001 + Radiation + Temozolomide In Newly Diagnosed Glioblastoma and Anaplastic Gliomas
EpicentRx, Inc.
NCT01904123 COMPLETED
STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain
M.D. Anderson Cancer Center
NCT03341806 COMPLETED
Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma
Icahn School of Medicine at Mount Sinai
NCT03374943 COMPLETED
A Trial of KB004 in Patients With Glioblastoma
Olivia Newton-John Cancer Research Institute
NCT03422094 TERMINATED
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
NCT03020602 COMPLETED
BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
Seema Nagpal
NCT04854044 WITHDRAWN
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
NCT02903069 COMPLETED
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Celgene
NCT03615404 COMPLETED
Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
Gary Archer Ph.D.
NCT03603379 COMPLETED
Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas
University Hospital, Basel, Switzerland
NCT03619239 COMPLETED
Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma
Genexine, Inc.
NCT04270461 WITHDRAWN
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
Jiujiang University Affiliated Hospital
NCT03707457 TERMINATED
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02502708 COMPLETED
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
NewLink Genetics Corporation
NCT03573986 TERMINATED
Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment
Abramson Cancer Center at Penn Medicine
NCT02378532 COMPLETED
The Addition of Chloroquine to Chemoradiation for Glioblastoma
Maastricht Radiation Oncology
NCT02820584 COMPLETED
A Phase I Study of Immunotherapy With GSC -Loaded Dendritic Cells in Patients With Recurrent Glioblastoma
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
NCT03480867 WITHDRAWN
Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)
McGill University Health Centre/Research Institute of the McGill University Health Centre
NCT03246113 TERMINATED
Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma
New York State Psychiatric Institute
NCT02337426 COMPLETED
Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Virginia Commonwealth University
NCT02853565 COMPLETED
A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme
CANbridge Life Sciences Ltd.
NCT02728349 COMPLETED
Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
NCT02718443 COMPLETED
VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma
Vaximm GmbH
NCT03275558 WITHDRAWN
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma
Center Trials & Treatment
NCT02365662 TERMINATED
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
AbbVie
NCT02254954 TERMINATED
Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma
Actelion
NCT02510950 TERMINATED
Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Washington University School of Medicine
NCT02648633 TERMINATED
Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma
University of Virginia
NCT01317212 WITHDRAWN
Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme
North Bristol NHS Trust
NCT03975829 ACTIVE NOT RECRUITING
Pediatric Long-Term Follow-up and Rollover Study
Novartis Pharmaceuticals
NCT05342883 ACTIVE NOT RECRUITING
GammaTile and Stupp in Newly Diagnosed GBM
GT Medical Technologies, Inc.
NCT05235737 RECRUITING
The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab
Medical University of Silesia
NCT06625047 COMPLETED
Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy
Mayo Clinic
NCT05900908 WITHDRAWN
Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy
GT Medical Technologies, Inc.
Data: ClinicalTrials.gov